Remarkably, the immune effect on CFC/LPC in NPM1-mutated AML patients markedly increased with specific CTLs against NPM1-mutated epitope and was stronger with the addition of anti-PD1 antibody to colony-forming immunoassays. Here, NPM1 is linked to acute myeloid leukemia.